These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 7448322)

  • 21. Deficiency of lymphocyte antigen recognition in Hodgkin's disease.
    Gaines JD; Gilmer MA; Remington JS
    Natl Cancer Inst Monogr; 1973 May; 36():117-21. PubMed ID: 4744572
    [No Abstract]   [Full Text] [Related]  

  • 22. Some immunological parameters in Hodgkin's disease.
    Dienstbier Z; Hermanská Z; Pĕnicka P; Zámecník J
    Neoplasma; 1988; 35(1):51-60. PubMed ID: 3352837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunodeficiency and lymphomas].
    Leoni P; Montroni M; Montillo M; Centurioni R; Salvi A; Fanciulli E
    G Clin Med; 1981 Sep; 62(9):648-55. PubMed ID: 7033028
    [No Abstract]   [Full Text] [Related]  

  • 24. [Staging laparotomy in Hodgkin's disease and non-Hodgkin lymphomas: indication, technic and results].
    Aeberhard P; Schröder R; Joss J
    Ther Umsch; 1981 Sep; 38(9):875-80. PubMed ID: 7292368
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of levamisole, thymic humoral factor and indomethacin on e-rosette formation of lymphocytes in Hodgkin's disease.
    Ramot B; Rosenthal E; Biniaminov M; Ben-Bassat I
    Isr J Med Sci; 1981 Apr; 17(4):232-5. PubMed ID: 7195385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunocompetent cells in malignant disease in man. II. Clinical and immunologic correlates in a case of non-Hodgkin's lymphoma.
    Algom D; Rapp E; Hamdy H; Keaney MA; Hirte W; Klaassen DJ; Richter M
    Can Med Assoc J; 1978 Jan; 118(2):168-71. PubMed ID: 757385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current status and future problems of non-Hodgkin's lymphoma. I. Special reference with staging of non-Hodgkin's lymphoma (author's transl)].
    Sakano T
    Rinsho Ketsueki; 1978 Jan; 19(1):1-8. PubMed ID: 344931
    [No Abstract]   [Full Text] [Related]  

  • 28. Hodgkin's disease and non-Hodgkin's lymphomas.
    Mauri C; Silingardi V; Perugini S; Quaglino D; Torelli U; Artusi T; Canossi GC; Curci G; De Pasquale A; Di Prisco AU; Emilia G; Federico M; Lusvarghi E; Manzini E; Romagnoli R; Gobbi GP
    Panminerva Med; 1980; 22(2):95-104. PubMed ID: 7208088
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunocompetence and malignant lymphoma: immunologic status before therapy.
    Anderson TC; Jones SE; Soehnlen BJ; Moon TE; Griffith K; Stanley P
    Cancer; 1981 Dec; 48(12):2702-9. PubMed ID: 6458352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization and expression of CT45 in Hodgkin's lymphoma.
    Heidebrecht HJ; Claviez A; Kruse ML; Pollmann M; Buck F; Harder S; Tiemann M; Dörffel W; Parwaresch R
    Clin Cancer Res; 2006 Aug; 12(16):4804-11. PubMed ID: 16914565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-year survival in Hodgkin's disease. The prospective value of immune status at diagnosis.
    van Rijswijk RE; de Meijer A; Sybesma JP; Kater L
    Cancer; 1986 Apr; 57(8):1489-96. PubMed ID: 2936444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
    Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
    Tzankov A; Meier C; Hirschmann P; Went P; Pileri SA; Dirnhofer S
    Haematologica; 2008 Feb; 93(2):193-200. PubMed ID: 18223287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Staging classification of malignant lymphoma].
    Takagi T
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1619-22. PubMed ID: 9725059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.
    Muenst S; Hoeller S; Dirnhofer S; Tzankov A
    Hum Pathol; 2009 Dec; 40(12):1715-22. PubMed ID: 19695683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating lymphoid cells in Hodgkin's disease.
    Fairley GH
    Natl Cancer Inst Monogr; 1973 May; 36():95-8. PubMed ID: 4270378
    [No Abstract]   [Full Text] [Related]  

  • 37. Evidence of Sternberg-Reed cells being derived from activated lymphocytes.
    Stein H; Gerdes J; Lemke H; Mason DY
    Haematol Blood Transfus; 1985; 29():441-4. PubMed ID: 4029737
    [No Abstract]   [Full Text] [Related]  

  • 38. Spleen lymphocyte populations in patients with Hodgkin's disease--properties of cells with different densities.
    Rocha B; Ferreira AA; Munn G; de Sousa M; Freitas AA
    Clin Exp Immunol; 1982 May; 48(2):300-6. PubMed ID: 7105487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Presence of cells with a high content of DNA in the circulating blood of 2 patients with malignant lymphoma. Blastic response of blood lymphocytes to PHA].
    Chilosi M; Nigro M
    Pathologica; 1974; 66(957-958):287-93. PubMed ID: 4453436
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunological study on Hodgkin's disease with special reference to lymphocyte inhibitor.
    Chen YC; Deng JS
    Taiwan Yi Xue Hui Za Zhi; 1981 Jan; 80(1):55-67. PubMed ID: 6946189
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.